cladribine, cytarabine,venetoclax

PreclinicalSmall molecule

TThe First Affiliated Hospital of Soochow University

cladribine, cytarabine,venetoclax is one of 4 small molecule programs targeting B-ALL. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

B-ALLRecruiting

B-ALLPreclinical

Recruiting

Competition

Competitive Landscape

3 competitors in B-ALL

#DrugCompanyPhaseTrials

Venclexta

AbbVie

Phase 1

1 2

Besponsa

WWyeth-Lederle Vaccines

Phase 1

2 3

Decadron

AAspen Global Incorporated

Phase 1

1 4

cladribine, cytarabine,venetoclax

TThe First Affiliated Hospital of Soochow University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

N/ARecruiting

B-ALL

NCT05657652

Clinical

Trials by Indication[1]

B-ALL1 trial

CAV Regimen for R/R Ph- B-ALL

Recruiting·TThe First Affiliated Hospital of Soochow University·N/A·NCT05657652·36 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for cladribine, cytarabine,venetoclax. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — cladribine, cytarabine,venetoclax compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for cladribine, cytarabine,venetoclax. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The First Affiliated Hospital of Soochow University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: TThe First Affiliated Hospital of Soochow University

cladribine, cytarabine,venetoclax

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

B-ALL1 trial

References

Drug Info

Quick Facts

Related News